Information regarding generic versions of Entresto is limited, as its primary patents are still active and have not yet expired. DrugPatentWatch.com indicates that the United States Patent for Entresto, which has the active ingredients sacubitril and valsartan, is set to expire in 2027 [1].
When Might Generic Entresto Become Available?
The availability of generic Entresto hinges on the expiration of its existing patents. Typically, once patents expire, other pharmaceutical companies can begin manufacturing and marketing generic versions of the drug. For Entresto, this is anticipated around 2027 in the United States [1]. However, patent disputes or extensions could alter this timeline.
What Are the Active Ingredients in Entresto?
Entresto contains a combination of two active ingredients: sacubitril and valsartan [1]. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin II receptor blocker (ARB). This combination works together to help reduce the risk of cardiovascular death and hospitalization for heart failure in certain patients.
How Does Entresto Compare to Other Heart Failure Medications?
Entresto represents a distinct therapeutic approach for heart failure with reduced ejection fraction (HFrEF). Unlike traditional ARBs or ACE inhibitors alone, Entresto's dual-acting mechanism targets both the renin-angiotensin-aldosterone system (RAAS) and the natriuretic peptide system. Clinical trials have demonstrated its superiority over enalapril (an ACE inhibitor) in reducing cardiovascular mortality and heart failure hospitalizations [2].
Who Manufactures Entresto?
The originator of Entresto is Novartis [1]. Generic versions would be produced by other pharmaceutical manufacturers once patent protections lapse and regulatory approvals are obtained.
What is the Patent Status of Entresto?
Entresto has patents protecting its composition of matter and methods of use. The primary U.S. patent is scheduled to expire in 2027 [1]. However, secondary patents related to formulations, manufacturing processes, or specific uses might exist and could influence the generic market entry. Patent litigation can also impact the exclusivity period.
Can Biosimilars of Entresto Enter the Market?
Entresto is a small molecule drug, not a biologic. Therefore, the concept of "biosimilars" does not apply. Generic drugs, which are chemically identical to the originator drug, are the relevant category for Entresto.
What Are the Risks and Side Effects Associated with Entresto?
Common side effects of Entresto can include low blood pressure (hypotension), high potassium levels (hyperkalemia), dizziness, cough, and kidney problems [2]. Angioedema, a serious allergic reaction causing swelling, is also a potential risk, particularly for patients with a history of angioedema related to ACE inhibitors or ARBs. Patients are advised to discuss any concerns about side effects with their healthcare providers.
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration